DOCS vs. NVO: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DOCS and NVO, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
DOCS is a standard domestic listing, while NVO trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | DOCS | NVO |
|---|---|---|
| Company Name | Doximity, Inc. | Novo Nordisk A/S |
| Country | United States | Denmark |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Technology | Pharmaceuticals |
| Market Capitalization | 11.99 billion USD | 226.64 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 24, 2021 | April 30, 1981 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of DOCS and NVO by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DOCS | NVO |
|---|---|---|
| 5-Day Price Return | 9.34% | 10.71% |
| 13-Week Price Return | 4.88% | -28.27% |
| 26-Week Price Return | 9.89% | -47.23% |
| 52-Week Price Return | 83.18% | 67.26% |
| Month-to-Date Return | 8.97% | 1.91% |
| Year-to-Date Return | 19.91% | -48.65% |
| 10-Day Avg. Volume | 2.40M | 15.64M |
| 3-Month Avg. Volume | 2.32M | 6.54M |
| 3-Month Volatility | 49.40% | 64.16% |
| Beta | 1.38 | 1.51 |
Profitability
Return on Equity (TTM)
DOCS
22.38%
Health Care Technology Industry
- Max
- 47.95%
- Q3
- 35.17%
- Median
- 13.74%
- Q1
- 11.05%
- Min
- 11.05%
DOCS’s Return on Equity of 22.38% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
NVO
77.86%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
NVO’s Return on Equity of 77.86% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
DOCS
39.13%
Health Care Technology Industry
- Max
- 51.50%
- Q3
- 45.32%
- Median
- 27.34%
- Q1
- 14.21%
- Min
- 14.21%
DOCS’s Net Profit Margin of 39.13% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
NVO
35.61%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
NVO’s Net Profit Margin of 35.61% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
DOCS
39.94%
Health Care Technology Industry
- Max
- 73.15%
- Q3
- 56.55%
- Median
- 26.97%
- Q1
- 22.10%
- Min
- 22.10%
DOCS’s Operating Profit Margin of 39.94% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
NVO
45.78%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
NVO’s Operating Profit Margin of 45.78% is exceptionally high, placing it well above the typical range for the Pharmaceuticals industry. This demonstrates outstanding efficiency in managing its core operations, which can be a result of strong pricing power or superior cost control.
Profitability at a Glance
| Symbol | DOCS | NVO |
|---|---|---|
| Return on Equity (TTM) | 22.38% | 77.86% |
| Return on Assets (TTM) | 19.29% | 24.22% |
| Net Profit Margin (TTM) | 39.13% | 35.61% |
| Operating Profit Margin (TTM) | 39.94% | 45.78% |
| Gross Profit Margin (TTM) | 90.20% | 83.95% |
Financial Strength
Current Ratio (MRQ)
DOCS
6.97
Health Care Technology Industry
- Max
- 7.04
- Q3
- 7.01
- Median
- 4.60
- Q1
- 2.96
- Min
- 0.31
DOCS’s Current Ratio of 6.97 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
NVO
0.78
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
DOCS
0.00
Health Care Technology Industry
- Max
- 0.06
- Q3
- 0.05
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, DOCS’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
NVO
0.59
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.59 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
DOCS
--
Health Care Technology Industry
- Max
- 224.12
- Q3
- 222.84
- Median
- 219.00
- Q1
- 181.50
- Min
- 169.00
Interest Coverage Ratio data for DOCS is currently unavailable.
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | DOCS | NVO |
|---|---|---|
| Current Ratio (MRQ) | 6.97 | 0.78 |
| Quick Ratio (MRQ) | 6.73 | 0.56 |
| Debt-to-Equity Ratio (MRQ) | 0.00 | 0.59 |
| Interest Coverage Ratio (TTM) | -- | 149.07 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 1.12%
- Q3
- 0.62%
- Median
- 0.12%
- Q1
- 0.00%
- Min
- 0.00%
DOCS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
NVO
3.59%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 3.59%, NVO offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
DOCS
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 72.22%
- Median
- 42.51%
- Q1
- 0.00%
- Min
- 0.00%
DOCS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
NVO
61.60%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 61.60% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | DOCS | NVO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 3.59% |
| Dividend Payout Ratio (TTM) | 0.00% | 61.60% |
Valuation
Price-to-Earnings Ratio (TTM)
DOCS
53.76
Health Care Technology Industry
- Max
- 343.51
- Q3
- 272.61
- Median
- 54.67
- Q1
- 36.04
- Min
- 31.57
DOCS’s P/E Ratio of 53.76 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
NVO
12.81
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 12.81 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
DOCS
21.04
Health Care Technology Industry
- Max
- 176.90
- Q3
- 98.12
- Median
- 16.38
- Q1
- 4.49
- Min
- 0.00
DOCS’s P/S Ratio of 21.04 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
NVO
4.56
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
NVO’s P/S Ratio of 4.56 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
DOCS
10.06
Health Care Technology Industry
- Max
- 117.60
- Q3
- 90.72
- Median
- 8.09
- Q1
- 3.83
- Min
- 3.06
DOCS’s P/B Ratio of 10.06 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
NVO
8.87
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
NVO’s P/B Ratio of 8.87 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | DOCS | NVO |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 53.76 | 12.81 |
| Price-to-Sales Ratio (TTM) | 21.04 | 4.56 |
| Price-to-Book Ratio (MRQ) | 10.06 | 8.87 |
| Price-to-Free Cash Flow Ratio (TTM) | 44.98 | 21.60 |